drugset / Trial / NCT00473525

12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin

NCT00473525

Phase 2 Completed 303 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this Phase 2a study is to evaluate the efficacy, safety and tolerability, of multiple parallel doses of PF-00734200 following oral administration to adult human subjects with T2DM who currently are on a stable dose of metformin.

Timeline

Start
2007-07
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Gosogliptin Small molecule 2 mg Oral
Subject Gosogliptin Small molecule 5 mg Oral
Subject Gosogliptin Small molecule 10 mg Oral
Subject Gosogliptin Small molecule 20 mg Oral